Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solation or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solation or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to compounds of the formula (I) wherein A, X and R1 to R9 are as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to novel compounds of formula (I): wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to compounds of the formula (I) wherein A, X and R1 to R9 are as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to novel compounds of formula (I): wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: The present invention relates to novel compounds which are pyrazolo[1,5-a]pyrimidines, and which modulate the activity of peroxisome proliferator-activated receptors (PPAR) &agr; and/or &ggr;. The said compounds are predicted to be useful in the treatment of metabolic diseases, e.g. type II diabetes.

Abstract: A method and apparatus for maintaining a fastening tab (20) of a hook and loop fastener system in a storage position on an article, such as a disposable diaper (10). The fastening tab (20) has a first end portion (122) for permanent attachment to the article and a distal end portion (126) provided with projecting hook members (30). The distal end portion (126), in a ready position of the fastening tab, stands free from the article. The distal end portion, in the storage position, contacts a surface of the article. The method includes the steps of attaching the first end portion (122) of the fastening tab (20) to the article, and folding the distal end portion (126) of the fastening tab over the first end portion (122) of the tab such that the hook members (30) contact the surface of the article.

Abstract: The invention relates to an inductive component that comprises a magnetic core (1), coil (6) and yoke (7, 10). According to the invention, the magnetic core (1) comprises a cylinder (2) that has been wound from wide strip material around a non-magnetic material (5) such as to obtain planar outer ends (8, 9). Two flanges (3, 4) are wound from two narrow strips at the outer ends (8, 9) of the cylinder. The coil (6) is wound around the centre part of the cylinder (2) between the flanges (3, 4). Finally, the yoke (7, 10) is wound from strip material around the magnet core (1).

Abstract: The present invention relates to a crosslinked hyaluronic acid derivative in which the crosslinking has been achieved by means of reaction with a phosphorus-containing reagent, especially a derivative of an acid of phosphorus (V). The invention also relates to the methods of producing such a product as well as its use as a slow release depot for administration of hylaluronic acid or a medicament incorporated in the gel.

Abstract: Methods of facilitating surgical operations that involve the eye or eye area comprise introducing an opthalmologically acceptable composition containing hyaluronic acid into the site of the surgical operation. The hyaluronic acid comprises a chemically unmodified sterilized hyaluronic acid substance having a weight average molecular weight of from 4,500,000 to 12,000,000 daltons, a zero shear viscosity of from 1,000 to 80,000 Pas as measured on a 1.3-1.6% (wv) solution of hyaluronic acid substance in physiological phosphate buffer, and an absorbance at 257 nm of less than 3.5 when measured on a 1% solution of hyaluronic acid substance in sodium chloride buffer in a 10 mm cuvette. Preferred sterilized solutions of hyaluronic acid comprise hyaluronic acid which is chemically unmodified from the naturally occurring hyaluronic acid and has a weight average molecular weight of from 4,500,000 to 8,000,000 daltons, a zero shear viscosity of from 1,000 to 20,000 Pas and an absorbance at 257 nm of less than 3.5.

Abstract: Method for extracapsular cataract extraction with or without posterior chamber intraocular lens implantation comprising chemical modification of the posterior surface of the lens capsule, at least in the optical portion of said capsule, for preventing cell attachment and growth.

Abstract: The invention is concerned with a UV absorbing plastics material to be used in intraocular lenses, said material having been produced by means of incorporating in the plastics monomer mixture, prior to the polymerization thereof, a combination of chromophores selected from two groups of substances.